-
TEVA NEUROSCIENCE, INC. et al v. WATSON PHARMA, INC. et al DC CAFC
- 2:10-cv-05078
- D.N.J.
- Judge: Claire C. Cecchi
+5
- Filed: 10/01/2010
- Closed: 09/26/2014
- Latest Docket Entry: 09/26/2014
- PACER
3
Plaintiffs
10
Defendants
1
Accused
Product
1
Patent-in-Suit
1,457
Days in
Litigation
-
TEVA NEUROSCIENCE, INC. et al v. WATSON PHARMA, INC. et al DC CAFC
- 2:10-cv-05078
- D.N.J.
- Judge: Claire C. Cecchi
+5
- Filed: 10/01/2010
- Closed: 09/26/2014
- Latest Docket Entry: 09/26/2014
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Referred Judges
Assigned Judge
Previously Presiding
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of treating a subject for Parkinson's disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the subject.
|
Valid
Entry 553 Entry 569 |
| 2 |
The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered orally.
|
Valid
Entry 553 Entry 569 |
| 17 |
The method of claim 1 which further comprises administering to the subject Levodopa in an amount relative to the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the disease.
|
Valid
Entry 553 Entry 569 |
| 18 |
The method of claim 1 which further comprises administering to the subject a decarboxylase inhibitor in an amount effective to ensure L-Dopa uptake.
|
Valid
Entry 553 Entry 569 |
| 19 |
The method of claim 18, wherein the decarboxylase inhibitor is Carbidopa.
|
Valid
Entry 553 Entry 569 |
-
Infringement
Mylan Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Azilect | US 5,453,446 A |
1, 2, 17, 18, 19
|
Infringement
Entry 553
|
Mylan Pharmaceuticals Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Azilect | US 5,453,446 A |
1, 2, 17, 18, 19
|
Infringement
Entry 553
|
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Azilect | US 5,453,446 A |
1, 2, 17, 18, 19
|
Infringement
Entry 553
|
Orchid Healthcare
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Azilect | US 5,453,446 A |
1, 2, 17, 18, 19
|
Infringement
Entry 553
|
Orgenus Pharma Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Azilect | US 5,453,446 A |
1, 2, 17, 18, 19
|
Infringement
Entry 553
|
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Azilect | US 5,453,446 A |
1, 2, 17, 18, 19
|
Infringement
Entry 553
|
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 0.5, 1.0 mg rasagiline mesylate tablets, ANDA No. 201971. | US 5,453,446 A |
1, 2, 17, 18, 19
|
Infringement
Entry 569
|
